Fundraising Fox

Clearside Biomedical

Alpharetta, US · Founded 2011 · Delaware corporation · 5 known investors

clearsidebio.com ↗

Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, it works to rehabilitate, use, and monetize its retained intellectual property.

BiotechHealthtechMedical Devices

Founders & leadership

CD
Charles DeignanExecutive
GN
Glenn NoronhaExecutive
DH
Daniel H. WhiteExecutive
CS
Christy ShafferNamed on SEC filing
CT
Clay ThorpNamed on SEC filing
MP
Mark PrausnitzNamed on SEC filing

Board

EZ
Evgeny ZaytsevBoard director
DYDerek Yoon
Derek YooninBoard directorPresident & CEO at Solasta Ventures
CL
Christy L. Shaffer, Ph.D.Board director
CBClay B. Thorp
Clay B. ThorpinBoard directorGeneral Partner at Hatteras Venture Partners
WH
William HumphriesBoard director
GC
Gerald Cagle, Ph.D.Board director

Investors · 5

HEALTHCARE ROYALTY PARTNERSNew York
Mountain Group CapitalNashville
Solasta VenturesBoston
HatterasreportedRaleigh
Hatteras Venture Partnersreported · 2 sourcesResearch Triangle · $500K – $4Mvia Clay Thorp · board

Reported raises · per SEC filings

Form D private placements

$40.6M disclosed across 6 rounds · 2012–2019

▶$3.3MraisedDec 2019 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • George LasezkayExecutive Officer, Director
  • Charles A. DeignanExecutive Officer
  • William D. HumphriesDirector
  • Clay B. ThorpDirector
  • Jeffrey L. EdwardsDirector
  • Christy ShafferDirector
  • Richard CroarkinDirector
Offering amount
$3.3M
Amount sold
$3.3M
First sale
Nov 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$320KraisedOct 2016 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William D. HumphriesDirector
  • Gerald Cagle, Ph.D.Director
  • Evgeny ZaytsevDirector
  • Derek YoonDirector
  • Christy L. Shaffer, Ph.D.Director
  • Charles DeignanExecutive Officer
  • Glenn NoronhaExecutive Officer
  • Clay B. ThorpDirector
  • Daniel H. WhiteExecutive Officer, Director
  • Richard CroarkinDirector
Offering amount
$320K
Amount sold
$320K
First sale
Sep 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14.4MraisedDec 2015 · 9 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charlie DeignanExecutive Officer
  • Clay ThorpDirector
  • William HumphriesDirector
  • Evgeny ZaytsevDirector
  • Christy ShafferDirector
  • Daniel WhiteExecutive Officer, Director, Promoter
  • Gerald D. CagleDirector
Offering amount
$20M
Amount sold
$14.4M
First sale
Nov 2015
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.2MraisedSep 2014 · 31 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christy ShafferDirector, Promoter
  • Clay ThorpDirector
  • Daniel H. WhiteExecutive Officer, Director, Promoter
  • Charles A. DeignanExecutive Officer
  • Glenn NoronhaExecutive Officer
  • Evgeny ZaytsevDirector
  • William HumphriesDirector
  • Mark PrausnitzDirector, Promoter
  • Gerald D. CagleDirector
Offering amount
$20M
Amount sold
$16.2M
Minimum investment
$50K
Finders' fees
$118K
Proceeds to insiders
$550K
First sale
Aug 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedMay 2014 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • William HumphriesDirector
  • Jerry CagleDirector
  • Clay ThorpDirector
  • Mark PrausnitzDirector
  • Charles A. DeignanExecutive Officer
  • Glenn NoronhaExecutive Officer
  • Daniel H. WhiteExecutive Officer, Director
  • Christy ShafferDirector
Offering amount
$6M
Amount sold
$3M
Proceeds to insiders
$450K
First sale
Apr 2014
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedFeb 2012 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christy ShafferDirector
  • Clay ThorpDirector
  • Daniel H. WhiteExecutive Officer
  • Mark PrausnitzDirector
Offering amount
$4M
Amount sold
$3.2M
Minimum investment
$37.5K
Proceeds to insiders
$500K
First sale
Jan 2012
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Robinhood14 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha12 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Stocktwits12 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Public11 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Simply Wall St10 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.

Companies competing with Clearside Biomedical for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Clearside Biomedical do?
Clearside Biomedical is an intellectual property holding, investment, and commercialization company focused on its suprachoroidal space (SCS) ocular drug-delivery platform and microinjector technology. Following its emergence from Chapter 11 in 2026, it works to rehabilitate, use, and monetize its retained intellectual property.
Who are Clearside Biomedical's investors?
Clearside Biomedical's investors include HEALTHCARE ROYALTY PARTNERS, Mountain Group Capital, Solasta Ventures, Hatteras, Hatteras Venture Partners.
How much funding has Clearside Biomedical raised?
Clearside Biomedical has disclosed $40.6M raised across 6 rounds.
Where is Clearside Biomedical headquartered?
Clearside Biomedical is headquartered in Alpharetta, US.